Exact Mass: 648.5176
Exact Mass Matches: 648.5176
Found 500 metabolites which its exact mass value is equals to given mass value 648.5176,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
PA(16:0/16:0)
PA(16:0/16:0) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(16:0/16:0), in particular, consists of one chain of palmitic acid at the C-1 position and one chain of palmitic acid at the C-2 position. The palmitic acid moiety is derived from fish oils, milk fats, vegetable oils and animal fats, while the palmitic acid moiety is derived from fish oils, milk fats, vegetable oils and animal fats. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids. Indeed, the concentration of phosphatidic acids is often over-estimated in tissues and biofluids as it can arise by inadvertent enzymatic hydrolysis during inappropriate storage or extraction conditions during analysis. The main biosynthetic route of phosphatidic acid in animal tissues involves sequential acylation of alpha-glycerophosphate by acyl-coA derivatives of fatty acids. PAs are biologically active lipids that can stimulate a large range of responses in many different cell types, such as platelet aggregation, smooth muscle contraction, in vivo vasoactive effects, chemotaxis, expression of adhesion molecules, increased tight junction permeability of endothelial cells, induction of stress fibres, modulation of cardiac contractility, and many others. Diacylglycerols (DAGs) can be converted to PAs by DAG kinases and indirect evidence supports the notion that PAs alter the excitability of neurons. Phospholipase Ds (PLDs), which catalyze the conversion of glycerolphospholipids, particularly phosphatidylcholine, to PAs and the conversion of N-arachidonoyl-phosphatidylethanolamine (NAPE) to anandamide and PAs are activated by several inflammatory mediators including bradykinin, ATP and glutamate. PAs activate downstream signaling pathways such as PKCs and mitogen-activated protein kinases (MAPKs), which are linked to an increase in sensitivity of sensory neurons either during inflammation or in chronic pain models. Circumstantial evidence that PAs are converted to DAGs. (PMID: 12618218, 16185776). [HMDB] PA(16:0/16:0) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(16:0/16:0), in particular, consists of one chain of palmitic acid at the C-1 position and one chain of palmitic acid at the C-2 position. The palmitic acid moiety is derived from fish oils, milk fats, vegetable oils and animal fats, while the palmitic acid moiety is derived from fish oils, milk fats, vegetable oils and animal fats. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids. Indeed, the concentration of phosphatidic acids is often over-estimated in tissues and biofluids as it can arise by inadvertent enzymatic hydrolysis during inappropriate storage or extraction conditions during analysis. The main biosynthetic route of phosphatidic acid in animal tissues involves sequential acylation of alpha-glycerophosphate by acyl-CoA derivatives of fatty acids. PAs are biologically active lipids that can stimulate a large range of responses in many different cell types, such as platelet aggregation, smooth muscle contraction, in vivo vasoactive effects, chemotaxis, expression of adhesion molecules, increased tight junction permeability of endothelial cells, induction of stress fibres, modulation of cardiac contractility, and many others. Diacylglycerols (DAGs) can be converted to PAs by DAG kinases and indirect evidence supports the notion that PAs alter the excitability of neurons. Phospholipase Ds (PLDs), which catalyze the conversion of glycerolphospholipids, particularly phosphatidylcholine, to PAs and the conversion of N-arachidonoyl-phosphatidylethanolamine (NAPE) to anandamide and PAs are activated by several inflammatory mediators including bradykinin, ATP and glutamate. PAs activate downstream signaling pathways such as PKCs and mitogen-activated protein kinases (MAPKs), which are linked to an increase in sensitivity of sensory neurons either during inflammation or in chronic pain models. Circumstantial evidence that PAs are converted to DAGs. (PMID: 12618218, 16185776).
CE(5M7)
CE(5M7) is a furan fatty acid ester of cholesterol or simply a cholesteryl ester (CE). Cholesteryl esters are much less polar than free cholesterol and appear to be the preferred form for transport in plasma and for storage. Cholesteryl esters do not contribute to membranes but are packed into intracellular lipid particles or lipoprotein particles. Because of the mechanism of synthesis, plasma cholesteryl esters tend to contain relatively high proportions of C18 fatty acids. Cholesteryl esters are major constituents of the adrenal glands and they also accumulate in the fatty lesions of atherosclerotic plaques. Cholesteryl esters are also major constituents of the lipoprotein particles carried in blood (HDL, LDL, VLDL). The cholesteryl esters in high-density lipoproteins (HDL) are synthesized largely by transfer of fatty acids to cholesterol from position sn-2 (or C-2) of phosphatidylcholine catalyzed by the enzyme lecithin cholesterol acyl transferase (LCAT). The enzyme also promotes the transfer of cholesterol from cells to HDL. As cholesteryl esters accumulate in the lipoprotein core, cholesterol is removed from its surface thus promoting the flow of cholesterol from cell membranes into HDL. This in turn leads to morphological changes in HDL, which grow and become spherical. Subsequently, cholesteryl esters are transferred to the other lipoprotein fractions LDL and VLDL, a reaction catalyzed by cholesteryl ester transfer protein. Another enzyme, acyl-CoA:cholesterol acyltransferase (ACAT) synthesizes cholesteryl esters from CoA esters of fatty acids and cholesterol. Cholesteryl ester hydrolases liberate cholesterol and free fatty acids when required for membrane and lipoprotein formation, and they also provide cholesterol for hormone synthesis in adrenal cells. The shorthand notation for CE(5M7) refers to the furan fatty acids 5-carbon carboxyalkyl moiety, the methyl substitution in the 3-position of its furan moiety, and its 7-carbon alkyl moiety.
CE(7M5)
CE(7M5) is a furan fatty acid ester of cholesterol or simply a cholesteryl ester (CE). Cholesteryl esters are much less polar than free cholesterol and appear to be the preferred form for transport in plasma and for storage. Cholesteryl esters do not contribute to membranes but are packed into intracellular lipid particles or lipoprotein particles. Because of the mechanism of synthesis, plasma cholesteryl esters tend to contain relatively high proportions of C18 fatty acids. Cholesteryl esters are major constituents of the adrenal glands and they also accumulate in the fatty lesions of atherosclerotic plaques. Cholesteryl esters are also major constituents of the lipoprotein particles carried in blood (HDL, LDL, VLDL). The cholesteryl esters in high-density lipoproteins (HDL) are synthesized largely by transfer of fatty acids to cholesterol from position sn-2 (or C-2) of phosphatidylcholine catalyzed by the enzyme lecithin cholesterol acyl transferase (LCAT). The enzyme also promotes the transfer of cholesterol from cells to HDL. As cholesteryl esters accumulate in the lipoprotein core, cholesterol is removed from its surface thus promoting the flow of cholesterol from cell membranes into HDL. This in turn leads to morphological changes in HDL, which grow and become spherical. Subsequently, cholesteryl esters are transferred to the other lipoprotein fractions LDL and VLDL, a reaction catalyzed by cholesteryl ester transfer protein. Another enzyme, acyl-CoA:cholesterol acyltransferase (ACAT) synthesizes cholesteryl esters from CoA esters of fatty acids and cholesterol. Cholesteryl ester hydrolases liberate cholesterol and free fatty acids when required for membrane and lipoprotein formation, and they also provide cholesterol for hormone synthesis in adrenal cells. The shorthand notation for CE(7M5) refers to the furan fatty acids 7-carbon carboxyalkyl moiety, the methyl substitution in the 3-position of its furan moiety, and its 5-carbon alkyl moiety.
CE(8F5)
CE(8F5) is a furan fatty acid ester of cholesterol or simply a cholesteryl ester (CE). Cholesteryl esters are much less polar than free cholesterol and appear to be the preferred form for transport in plasma and for storage. Cholesteryl esters do not contribute to membranes but are packed into intracellular lipid particles or lipoprotein particles. Because of the mechanism of synthesis, plasma cholesteryl esters tend to contain relatively high proportions of C18 fatty acids. Cholesteryl esters are major constituents of the adrenal glands and they also accumulate in the fatty lesions of atherosclerotic plaques. Cholesteryl esters are also major constituents of the lipoprotein particles carried in blood (HDL, LDL, VLDL). The cholesteryl esters in high-density lipoproteins (HDL) are synthesized largely by transfer of fatty acids to cholesterol from position sn-2 (or C-2) of phosphatidylcholine catalyzed by the enzyme lecithin cholesterol acyl transferase (LCAT). The enzyme also promotes the transfer of cholesterol from cells to HDL. As cholesteryl esters accumulate in the lipoprotein core, cholesterol is removed from its surface thus promoting the flow of cholesterol from cell membranes into HDL. This in turn leads to morphological changes in HDL, which grow and become spherical. Subsequently, cholesteryl esters are transferred to the other lipoprotein fractions LDL and VLDL, a reaction catalyzed by cholesteryl ester transfer protein. Another enzyme, acyl-CoA:cholesterol acyltransferase (ACAT) synthesizes cholesteryl esters from CoA esters of fatty acids and cholesterol. Cholesteryl ester hydrolases liberate cholesterol and free fatty acids when required for membrane and lipoprotein formation, and they also provide cholesterol for hormone synthesis in adrenal cells. The shorthand notation for CE(8F5) refers to the furan fatty acids 8-carbon carboxyalkyl moiety, the non-methylated furan moiety, and its 5-carbon alkyl moiety.
CE(9M3)
CE(9M3) is a furan fatty acid ester of cholesterol or simply a cholesteryl ester (CE). Cholesteryl esters are much less polar than free cholesterol and appear to be the preferred form for transport in plasma and for storage. Cholesteryl esters do not contribute to membranes but are packed into intracellular lipid particles or lipoprotein particles. Because of the mechanism of synthesis, plasma cholesteryl esters tend to contain relatively high proportions of C18 fatty acids. Cholesteryl esters are major constituents of the adrenal glands and they also accumulate in the fatty lesions of atherosclerotic plaques. Cholesteryl esters are also major constituents of the lipoprotein particles carried in blood (HDL, LDL, VLDL). The cholesteryl esters in high-density lipoproteins (HDL) are synthesized largely by transfer of fatty acids to cholesterol from position sn-2 (or C-2) of phosphatidylcholine catalyzed by the enzyme lecithin cholesterol acyl transferase (LCAT). The enzyme also promotes the transfer of cholesterol from cells to HDL. As cholesteryl esters accumulate in the lipoprotein core, cholesterol is removed from its surface thus promoting the flow of cholesterol from cell membranes into HDL. This in turn leads to morphological changes in HDL, which grow and become spherical. Subsequently, cholesteryl esters are transferred to the other lipoprotein fractions LDL and VLDL, a reaction catalyzed by cholesteryl ester transfer protein. Another enzyme, acyl-CoA:cholesterol acyltransferase (ACAT) synthesizes cholesteryl esters from CoA esters of fatty acids and cholesterol. Cholesteryl ester hydrolases liberate cholesterol and free fatty acids when required for membrane and lipoprotein formation, and they also provide cholesterol for hormone synthesis in adrenal cells. The shorthand notation for CE(9M3) refers to the furan fatty acids 9-carbon carboxyalkyl moiety, the methyl substitution in the 3-position of its furan moiety, and its 3-carbon alkyl moiety.
PA(10:0/22:0)
PA(10:0/22:0) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(10:0/22:0), in particular, consists of one chain of capric acid at the C-1 position and one chain of behenic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.
PA(18:0/14:0)
PA(18:0/14:0) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(18:0/14:0), in particular, consists of one chain of stearic acid at the C-1 position and one chain of myristic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.
PA(20:0/12:0)
PA(20:0/12:0) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(20:0/12:0), in particular, consists of one chain of arachidic acid at the C-1 position and one chain of lauric acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.
PA(22:0/10:0)
PA(22:0/10:0) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(22:0/10:0), in particular, consists of one chain of behenic acid at the C-1 position and one chain of capric acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.
PA(10:0/i-22:0)
PA(10:0/i-22:0) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(10:0/i-22:0), in particular, consists of one chain of capric acid at the C-1 position and one chain of isodocosanoic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.
PA(20:0/i-12:0)
PA(20:0/i-12:0) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(20:0/i-12:0), in particular, consists of one chain of arachidic acid at the C-1 position and one chain of isododecanoic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.
PA(8:0/i-24:0)
PA(8:0/i-24:0) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(8:0/i-24:0), in particular, consists of one chain of caprylic acid at the C-1 position and one chain of isotetracosanoic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.
PA(a-13:0/i-19:0)
PA(a-13:0/i-19:0) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(a-13:0/i-19:0), in particular, consists of one chain of anteisotridecanoic acid at the C-1 position and one chain of isononadecanoic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.
PA(i-12:0/i-20:0)
PA(i-12:0/i-20:0) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(i-12:0/i-20:0), in particular, consists of one chain of isododecanoic acid at the C-1 position and one chain of isoeicosanoic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.
PA(i-13:0/i-19:0)
PA(i-13:0/i-19:0) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(i-13:0/i-19:0), in particular, consists of one chain of isotridecanoic acid at the C-1 position and one chain of isononadecanoic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.
PA(i-20:0/12:0)
PA(i-20:0/12:0) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(i-20:0/12:0), in particular, consists of one chain of isoeicosanoic acid at the C-1 position and one chain of lauric acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.
PA(i-20:0/i-12:0)
PA(i-20:0/i-12:0) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(i-20:0/i-12:0), in particular, consists of one chain of isoeicosanoic acid at the C-1 position and one chain of isododecanoic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.
PA(i-22:0/10:0)
PA(i-22:0/10:0) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(i-22:0/10:0), in particular, consists of one chain of isodocosanoic acid at the C-1 position and one chain of capric acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.
PA(i-24:0/8:0)
PA(i-24:0/8:0) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(i-24:0/8:0), in particular, consists of one chain of isotetracosanoic acid at the C-1 position and one chain of caprylic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.
2,3-Bis(palmitoyloxy)propyl dihydrogen phosphate
Menaquinone-7
DG(16:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/0:0)
DG(16:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(16:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/16:0/0:0)
DG(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/16:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/16:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(16:0/0:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R))
DG(16:0/0:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/0:0/16:0)
DG(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/0:0/16:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(16:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/0:0)
DG(16:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(16:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/16:0/0:0)
DG(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/16:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/16:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(16:0/0:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S))
DG(16:0/0:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/0:0/16:0)
DG(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/0:0/16:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(16:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/0:0)
DG(16:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(16:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/16:0/0:0)
DG(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/16:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/16:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(16:0/0:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R))
DG(16:0/0:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/0:0/16:0)
DG(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/0:0/16:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(17:0/20:3(6,8,11)-OH(5)/0:0)
DG(17:0/20:3(6,8,11)-OH(5)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(17:0/20:3(6,8,11)-OH(5)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(20:3(6,8,11)-OH(5)/17:0/0:0)
DG(20:3(6,8,11)-OH(5)/17:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(20:3(6,8,11)-OH(5)/17:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(17:0/0:0/20:3(6,8,11)-OH(5))
DG(17:0/0:0/20:3(6,8,11)-OH(5)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(20:3(6,8,11)-OH(5)/0:0/17:0)
DG(20:3(6,8,11)-OH(5)/0:0/17:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(19:0/18:2(10E,12Z)+=O(9)/0:0)
DG(19:0/18:2(10E,12Z)+=O(9)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(19:0/18:2(10E,12Z)+=O(9)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(18:2(10E,12Z)+=O(9)/19:0/0:0)
DG(18:2(10E,12Z)+=O(9)/19:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(18:2(10E,12Z)+=O(9)/19:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(19:0/0:0/18:2(10E,12Z)+=O(9))
DG(19:0/0:0/18:2(10E,12Z)+=O(9)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(18:2(10E,12Z)+=O(9)/0:0/19:0)
DG(18:2(10E,12Z)+=O(9)/0:0/19:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(19:0/18:2(9Z,11E)+=O(13)/0:0)
DG(19:0/18:2(9Z,11E)+=O(13)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(19:0/18:2(9Z,11E)+=O(13)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(18:2(9Z,11E)+=O(13)/19:0/0:0)
DG(18:2(9Z,11E)+=O(13)/19:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(18:2(9Z,11E)+=O(13)/19:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(19:0/0:0/18:2(9Z,11E)+=O(13))
DG(19:0/0:0/18:2(9Z,11E)+=O(13)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(18:2(9Z,11E)+=O(13)/0:0/19:0)
DG(18:2(9Z,11E)+=O(13)/0:0/19:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(19:0/18:3(10,12,15)-OH(9)/0:0)
DG(19:0/18:3(10,12,15)-OH(9)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(19:0/18:3(10,12,15)-OH(9)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(18:3(10,12,15)-OH(9)/19:0/0:0)
DG(18:3(10,12,15)-OH(9)/19:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(18:3(10,12,15)-OH(9)/19:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(19:0/0:0/18:3(10,12,15)-OH(9))
DG(19:0/0:0/18:3(10,12,15)-OH(9)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(18:3(10,12,15)-OH(9)/0:0/19:0)
DG(18:3(10,12,15)-OH(9)/0:0/19:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(19:0/18:3(9,11,15)-OH(13)/0:0)
DG(19:0/18:3(9,11,15)-OH(13)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(19:0/18:3(9,11,15)-OH(13)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(18:3(9,11,15)-OH(13)/19:0/0:0)
DG(18:3(9,11,15)-OH(13)/19:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(18:3(9,11,15)-OH(13)/19:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(19:0/0:0/18:3(9,11,15)-OH(13))
DG(19:0/0:0/18:3(9,11,15)-OH(13)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(18:3(9,11,15)-OH(13)/0:0/19:0)
DG(18:3(9,11,15)-OH(13)/0:0/19:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(a-17:0/20:3(6,8,11)-OH(5)/0:0)
DG(a-17:0/20:3(6,8,11)-OH(5)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(a-17:0/20:3(6,8,11)-OH(5)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(20:3(6,8,11)-OH(5)/a-17:0/0:0)
DG(20:3(6,8,11)-OH(5)/a-17:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(20:3(6,8,11)-OH(5)/a-17:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(a-17:0/0:0/20:3(6,8,11)-OH(5))
DG(a-17:0/0:0/20:3(6,8,11)-OH(5)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(20:3(6,8,11)-OH(5)/0:0/a-17:0)
DG(20:3(6,8,11)-OH(5)/0:0/a-17:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(i-16:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/0:0)
DG(i-16:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(i-16:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/i-16:0/0:0)
DG(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/i-16:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/i-16:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(i-16:0/0:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R))
DG(i-16:0/0:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/0:0/i-16:0)
DG(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/0:0/i-16:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(i-16:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/0:0)
DG(i-16:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(i-16:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/i-16:0/0:0)
DG(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/i-16:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/i-16:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(i-16:0/0:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S))
DG(i-16:0/0:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/0:0/i-16:0)
DG(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/0:0/i-16:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(i-16:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/0:0)
DG(i-16:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(i-16:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/i-16:0/0:0)
DG(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/i-16:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/i-16:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(i-16:0/0:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R))
DG(i-16:0/0:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/0:0/i-16:0)
DG(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/0:0/i-16:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(i-17:0/20:3(6,8,11)-OH(5)/0:0)
DG(i-17:0/20:3(6,8,11)-OH(5)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(i-17:0/20:3(6,8,11)-OH(5)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(20:3(6,8,11)-OH(5)/i-17:0/0:0)
DG(20:3(6,8,11)-OH(5)/i-17:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(20:3(6,8,11)-OH(5)/i-17:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(i-17:0/0:0/20:3(6,8,11)-OH(5))
DG(i-17:0/0:0/20:3(6,8,11)-OH(5)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(20:3(6,8,11)-OH(5)/0:0/i-17:0)
DG(20:3(6,8,11)-OH(5)/0:0/i-17:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(i-19:0/18:2(10E,12Z)+=O(9)/0:0)
DG(i-19:0/18:2(10E,12Z)+=O(9)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(i-19:0/18:2(10E,12Z)+=O(9)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(18:2(10E,12Z)+=O(9)/i-19:0/0:0)
DG(18:2(10E,12Z)+=O(9)/i-19:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(18:2(10E,12Z)+=O(9)/i-19:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(i-19:0/0:0/18:2(10E,12Z)+=O(9))
DG(i-19:0/0:0/18:2(10E,12Z)+=O(9)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(18:2(10E,12Z)+=O(9)/0:0/i-19:0)
DG(18:2(10E,12Z)+=O(9)/0:0/i-19:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(i-19:0/18:2(9Z,11E)+=O(13)/0:0)
DG(i-19:0/18:2(9Z,11E)+=O(13)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(i-19:0/18:2(9Z,11E)+=O(13)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(18:2(9Z,11E)+=O(13)/i-19:0/0:0)
DG(18:2(9Z,11E)+=O(13)/i-19:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(18:2(9Z,11E)+=O(13)/i-19:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(i-19:0/0:0/18:2(9Z,11E)+=O(13))
DG(i-19:0/0:0/18:2(9Z,11E)+=O(13)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(18:2(9Z,11E)+=O(13)/0:0/i-19:0)
DG(18:2(9Z,11E)+=O(13)/0:0/i-19:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(i-19:0/18:3(10,12,15)-OH(9)/0:0)
DG(i-19:0/18:3(10,12,15)-OH(9)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(i-19:0/18:3(10,12,15)-OH(9)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(18:3(10,12,15)-OH(9)/i-19:0/0:0)
DG(18:3(10,12,15)-OH(9)/i-19:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(18:3(10,12,15)-OH(9)/i-19:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(i-19:0/0:0/18:3(10,12,15)-OH(9))
DG(i-19:0/0:0/18:3(10,12,15)-OH(9)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(18:3(10,12,15)-OH(9)/0:0/i-19:0)
DG(18:3(10,12,15)-OH(9)/0:0/i-19:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(i-19:0/18:3(9,11,15)-OH(13)/0:0)
DG(i-19:0/18:3(9,11,15)-OH(13)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(i-19:0/18:3(9,11,15)-OH(13)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(18:3(9,11,15)-OH(13)/i-19:0/0:0)
DG(18:3(9,11,15)-OH(13)/i-19:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(18:3(9,11,15)-OH(13)/i-19:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(i-19:0/0:0/18:3(9,11,15)-OH(13))
DG(i-19:0/0:0/18:3(9,11,15)-OH(13)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(18:3(9,11,15)-OH(13)/0:0/i-19:0)
DG(18:3(9,11,15)-OH(13)/0:0/i-19:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
1-(alpha-D-glucopyranosyloxy)-(3R,27S,29R)-triacontanetriol
(2S,3R,26S,27S)-2,27-diamino-1,3,26-trihydroxynonacosan-18-one-1-beta-D-glucoside|calyxoside
(2S,3R,4E,2R)-2-N-(2-hydroxy-13-methyltetradecanoyl)-15-methyl-4-hexadecasphingenyl-1-phosphoethanolamine
PE-Cer(d14:1(4E)/18:0(2OH))
1-(O-alpha-D-glucopyranosyl)-(1,3R,27S,29R)-triacontanetetraol
1-(O-alpha-D-galactopyranosyl)-(1,3R,27S,29R)-triacontanetetraol
1-(8-[5]-ladderane-octanoyl)-2-(8-[3]-ladderane-octanyl)-sn-glycerol
1-(O-alpha-D-glucopyranosyl)-(1,3R,27S,29R)-triacontanetetrol
1-(O-alpha-D-galactopyranosyl)-(1,3R,27S,29R)-triacontanetetrol
Menaquinone-7
Menaquinone-7 is a menaquinone whose side-chain contains seven isoprene units in an all-trans-configutation. It has a role as a Mycoplasma genitalium metabolite, a bone density conservation agent, an Escherichia coli metabolite, a human blood serum metabolite and a cofactor. D006401 - Hematologic Agents > D003029 - Coagulants > D006490 - Hemostatics Menaquinone 7. CAS Common Chemistry. CAS, a division of the American Chemical Society, n.d. https://commonchemistry.cas.org/detail?cas_rn=2124-57-4 (retrieved 2024-09-09) (CAS RN: 2124-57-4). Licensed under the Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0).
2-[2-[3,4-Bis(2-methoxyethoxy)oxolan-2-yl]-2-(2-methoxyethoxy)ethoxy]ethyl octadecanoate
[(2S)-1-heptadecanoyloxy-3-hydroxypropan-2-yl] (6E,8E,11E)-5-hydroxyicosa-6,8,11-trienoate
[(2S)-2-heptadecanoyloxy-3-hydroxypropyl] (6E,8E,11E)-5-hydroxyicosa-6,8,11-trienoate
[(2R)-3-heptadecanoyloxy-2-hydroxypropyl] (6E,8E,11E)-5-hydroxyicosa-6,8,11-trienoate
[(2S)-3-heptadecanoyloxy-2-hydroxypropyl] (6E,8E,11E)-5-hydroxyicosa-6,8,11-trienoate
[(2S)-3-hydroxy-2-[(10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoyl]oxypropyl] nonadecanoate
[(2S)-1-hydroxy-3-[(10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoyl]oxypropan-2-yl] nonadecanoate
[(2R)-2-hydroxy-3-[(10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoyl]oxypropyl] nonadecanoate
[(2S)-2-hydroxy-3-[(10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoyl]oxypropyl] nonadecanoate
[(2S)-3-hydroxy-2-[(9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoyl]oxypropyl] nonadecanoate
[(2S)-1-hydroxy-3-[(9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoyl]oxypropan-2-yl] nonadecanoate
[(2R)-2-hydroxy-3-[(9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoyl]oxypropyl] nonadecanoate
[(2S)-2-hydroxy-3-[(9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoyl]oxypropyl] nonadecanoate
[3-Hydroxy-2-(propanoylamino)heptacosyl] 2-(trimethylazaniumyl)ethyl phosphate
[2-(Butanoylamino)-3-hydroxyhexacosyl] 2-(trimethylazaniumyl)ethyl phosphate
[3-Hydroxy-2-(octanoylamino)docosyl] 2-(trimethylazaniumyl)ethyl phosphate
[1-hydroxy-3-[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoxy]propan-2-yl] (10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoate
[1-hydroxy-3-[(6Z,9Z,12Z,15Z,18Z,21Z)-tetracosa-6,9,12,15,18,21-hexaenoxy]propan-2-yl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate
[1-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoxy]-3-hydroxypropan-2-yl] (9Z,12Z,15Z,18Z,21Z)-tetracosa-9,12,15,18,21-pentaenoate
[1-hydroxy-3-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoxy]propan-2-yl] (7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoate
[1-hydroxy-3-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoxy]propan-2-yl] (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoate
[1-hydroxy-3-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoxy]propan-2-yl] (8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoate
[1-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoxy]-3-hydroxypropan-2-yl] (9Z,12Z,15Z)-octadeca-9,12,15-trienoate
[3-Hydroxy-2-(pentanoylamino)pentacosyl] 2-(trimethylazaniumyl)ethyl phosphate
[1-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoxy]-3-hydroxypropan-2-yl] (6Z,9Z,12Z,15Z,18Z,21Z)-tetracosa-6,9,12,15,18,21-hexaenoate
[3-Hydroxy-2-(nonanoylamino)henicosyl] 2-(trimethylazaniumyl)ethyl phosphate
[2-(Henicosanoylamino)-3-hydroxynonyl] 2-(trimethylazaniumyl)ethyl phosphate
[2-(Heptanoylamino)-3-hydroxytricosyl] 2-(trimethylazaniumyl)ethyl phosphate
[1-[(7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoxy]-3-hydroxypropan-2-yl] (6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoate
[1-[(10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoxy]-3-hydroxypropan-2-yl] (3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoate
[2-(Hexanoylamino)-3-hydroxytetracosyl] 2-(trimethylazaniumyl)ethyl phosphate
[1-hydroxy-3-[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoxy]propan-2-yl] (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate
(2-Acetamido-3-hydroxyoctacosyl) 2-(trimethylazaniumyl)ethyl phosphate
[1-hydroxy-3-[(9Z,12Z,15Z,18Z,21Z)-tetracosa-9,12,15,18,21-pentaenoxy]propan-2-yl] (4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoate
[2-(Decanoylamino)-3-hydroxyicosyl] 2-(trimethylazaniumyl)ethyl phosphate
[3-Hydroxy-2-(nonadecanoylamino)undecyl] 2-(trimethylazaniumyl)ethyl phosphate
[3-Hydroxy-2-(icosanoylamino)decyl] 2-(trimethylazaniumyl)ethyl phosphate
[2-(Heptadecanoylamino)-3-hydroxytridecyl] 2-(trimethylazaniumyl)ethyl phosphate
4-[12-hydroxy-10,13-dimethyl-3-[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoyl]oxy-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid
[3-Hydroxy-2-(octadecanoylamino)dodecyl] 2-(trimethylazaniumyl)ethyl phosphate
[3-Hydroxy-2-(undecanoylamino)nonadecyl] 2-(trimethylazaniumyl)ethyl phosphate
2,3-di(octanoyloxy)propyl (11Z,14Z)-henicosa-11,14-dienoate
(2-nonanoyloxy-3-octanoyloxypropyl) (11Z,14Z)-icosa-11,14-dienoate
2,3-di(nonanoyloxy)propyl (9Z,12Z)-nonadeca-9,12-dienoate
(3-octanoyloxy-2-undecanoyloxypropyl) (9Z,12Z)-octadeca-9,12-dienoate
(2-decanoyloxy-3-octanoyloxypropyl) (9Z,12Z)-nonadeca-9,12-dienoate
[3-nonanoyloxy-2-[(Z)-tridec-9-enoyl]oxypropyl] (Z)-pentadec-9-enoate
(2-dodecanoyloxy-3-nonanoyloxypropyl) (9Z,12Z)-hexadeca-9,12-dienoate
(3-nonanoyloxy-2-undecanoyloxypropyl) (9Z,12Z)-heptadeca-9,12-dienoate
[3-octanoyloxy-2-[(Z)-tetradec-9-enoyl]oxypropyl] (Z)-pentadec-9-enoate
[3-nonanoyloxy-2-[(Z)-tetradec-9-enoyl]oxypropyl] (Z)-tetradec-9-enoate
[3-octanoyloxy-2-[(Z)-tridec-9-enoyl]oxypropyl] (Z)-hexadec-9-enoate
(3-octanoyloxy-2-tridecanoyloxypropyl) (9Z,12Z)-hexadeca-9,12-dienoate
(2-dodecanoyloxy-3-octanoyloxypropyl) (9Z,12Z)-heptadeca-9,12-dienoate
(2-decanoyloxy-3-nonanoyloxypropyl) (9Z,12Z)-octadeca-9,12-dienoate
[2-[(Z)-tridec-9-enoyl]oxy-3-undecanoyloxypropyl] (Z)-tridec-9-enoate
2,3-di(decanoyloxy)propyl (9Z,12Z)-heptadeca-9,12-dienoate
[3-decanoyloxy-2-[(Z)-tridec-9-enoyl]oxypropyl] (Z)-tetradec-9-enoate
(3-decanoyloxy-2-undecanoyloxypropyl) (9Z,12Z)-hexadeca-9,12-dienoate
[2-(Docosanoylamino)-3-hydroxyoctyl] 2-(trimethylazaniumyl)ethyl phosphate
[2-(Hexadecanoylamino)-3-hydroxytetradecyl] 2-(trimethylazaniumyl)ethyl phosphate
[3-Hydroxy-2-(pentadecanoylamino)pentadecyl] 2-(trimethylazaniumyl)ethyl phosphate
[3-Hydroxy-2-(tetradecanoylamino)hexadecyl] 2-(trimethylazaniumyl)ethyl phosphate
[3-Hydroxy-2-(tridecanoylamino)heptadecyl] 2-(trimethylazaniumyl)ethyl phosphate
2,3-bis[[(Z)-dodec-5-enoyl]oxy]propyl tridecanoate
[2-[(6Z,9Z)-dodeca-6,9-dienoyl]oxy-3-dodecanoyloxypropyl] tridecanoate
[3-dodecanoyloxy-2-[(Z)-dodec-5-enoyl]oxypropyl] (Z)-tridec-8-enoate
N-(tridecanoyl)-heptadecasphinganine-1-phosphocholine
N-(pentadecanoyl)-pentadecasphinganine-1-phosphocholine
N-(hexadecanoyl)-tetradecasphinganine-1-phosphocholine
[1-carboxy-3-[3-[(E)-dec-4-enoyl]oxy-2-[(11E,13E,15E)-octadeca-11,13,15-trienoyl]oxypropoxy]propyl]-trimethylazanium
[(2R,3S)-2-(decanoylamino)-3-hydroxyicosyl] 2-(trimethylazaniumyl)ethyl phosphate
[1-carboxy-3-[2-[(3E,6E,9E)-dodeca-3,6,9-trienoyl]oxy-3-[(E)-hexadec-7-enoyl]oxypropoxy]propyl]-trimethylazanium
[1-carboxy-3-[3-[(6E,9E,12E)-pentadeca-6,9,12-trienoyl]oxy-2-[(E)-tridec-8-enoyl]oxypropoxy]propyl]-trimethylazanium
2-[[(2S)-3-[(E)-hexadec-1-enoxy]-2-undecanoyloxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
[1-carboxy-3-[3-dodecanoyloxy-2-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxypropoxy]propyl]-trimethylazanium
[1-carboxy-3-[3-[(E)-dodec-5-enoyl]oxy-2-[(9E,11E,13E)-hexadeca-9,11,13-trienoyl]oxypropoxy]propyl]-trimethylazanium
[1-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-hydroxypropan-2-yl] (11E,14E,17E,20E)-tricosa-11,14,17,20-tetraenoate
[1-carboxy-3-[3-[(3E,6E,9E)-dodeca-3,6,9-trienoyl]oxy-2-[(E)-hexadec-7-enoyl]oxypropoxy]propyl]-trimethylazanium
[1-carboxy-3-[3-[(4E,7E)-deca-4,7-dienoyl]oxy-2-[(10E,12E)-octadeca-10,12-dienoyl]oxypropoxy]propyl]-trimethylazanium
[1-carboxy-3-[2-[(8E,11E,14E)-heptadeca-8,11,14-trienoyl]oxy-3-[(E)-undec-4-enoyl]oxypropoxy]propyl]-trimethylazanium
[1-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxy-3-hydroxypropan-2-yl] (8E,11E,14E,17E,20E)-tricosa-8,11,14,17,20-pentaenoate
[1-[(9E,11E,13E)-hexadeca-9,11,13-trienoyl]oxy-3-hydroxypropan-2-yl] (5E,8E,11E,14E,17E,20E)-tricosa-5,8,11,14,17,20-hexaenoate
[1-carboxy-3-[2-[(6E,9E)-dodeca-6,9-dienoyl]oxy-3-[(4E,7E)-hexadeca-4,7-dienoyl]oxypropoxy]propyl]-trimethylazanium
[1-carboxy-3-[2-[(4E,7E)-deca-4,7-dienoyl]oxy-3-[(10E,12E)-octadeca-10,12-dienoyl]oxypropoxy]propyl]-trimethylazanium
[1-carboxy-3-[3-[(6E,9E)-dodeca-6,9-dienoyl]oxy-2-[(4E,7E)-hexadeca-4,7-dienoyl]oxypropoxy]propyl]-trimethylazanium
[1-carboxy-3-[2-dodecanoyloxy-3-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxypropoxy]propyl]-trimethylazanium
[1-carboxy-3-[2-[(E)-dec-4-enoyl]oxy-3-[(11E,13E,15E)-octadeca-11,13,15-trienoyl]oxypropoxy]propyl]-trimethylazanium
[1-carboxy-3-[2-decanoyloxy-3-[(9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoyl]oxypropoxy]propyl]-trimethylazanium
[1-carboxy-3-[3-[(8E,11E,14E)-heptadeca-8,11,14-trienoyl]oxy-2-[(E)-undec-4-enoyl]oxypropoxy]propyl]-trimethylazanium
[1-carboxy-3-[2-[(6E,9E,12E)-pentadeca-6,9,12-trienoyl]oxy-3-[(E)-tridec-8-enoyl]oxypropoxy]propyl]-trimethylazanium
[3-[2,3-bis[[(7E,9E)-tetradeca-7,9-dienoyl]oxy]propoxy]-1-carboxypropyl]-trimethylazanium
[1-carboxy-3-[2-[(E)-dodec-5-enoyl]oxy-3-[(9E,11E,13E)-hexadeca-9,11,13-trienoyl]oxypropoxy]propyl]-trimethylazanium
[1-carboxy-3-[3-[(5E,8E,11E)-tetradeca-5,8,11-trienoyl]oxy-2-[(E)-tetradec-9-enoyl]oxypropoxy]propyl]-trimethylazanium
[1-carboxy-3-[3-decanoyloxy-2-[(9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoyl]oxypropoxy]propyl]-trimethylazanium
[1-carboxy-3-[2-[(5E,8E,11E)-tetradeca-5,8,11-trienoyl]oxy-3-[(E)-tetradec-9-enoyl]oxypropoxy]propyl]-trimethylazanium
2-[hydroxy-[2-nonanoyloxy-3-[(Z)-octadec-9-enoxy]propoxy]phosphoryl]oxyethyl-trimethylazanium
[1-carboxy-3-[2-[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoyl]oxy-3-octanoyloxypropoxy]propyl]-trimethylazanium
[3-[3-butanoyloxy-2-[(12Z,15Z,18Z,21Z)-tetracosa-12,15,18,21-tetraenoyl]oxypropoxy]-1-carboxypropyl]-trimethylazanium
2-[hydroxy-[3-[(Z)-tetradec-9-enoxy]-2-tridecanoyloxypropoxy]phosphoryl]oxyethyl-trimethylazanium
[1-carboxy-3-[3-decanoyloxy-2-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoyl]oxypropoxy]propyl]-trimethylazanium
[1-carboxy-3-[2-[(10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoyl]oxy-3-hexanoyloxypropoxy]propyl]-trimethylazanium
[1-carboxy-3-[3-dodecanoyloxy-2-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxypropoxy]propyl]-trimethylazanium
2-[[3-[(Z)-hexadec-9-enoxy]-2-undecanoyloxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[3-tetradecoxy-2-[(Z)-tridec-9-enoyl]oxypropoxy]phosphoryl]oxyethyl-trimethylazanium
[3-[3-acetyloxy-2-[(14Z,17Z,20Z,23Z)-hexacosa-14,17,20,23-tetraenoyl]oxypropoxy]-1-carboxypropyl]-trimethylazanium
2-[hydroxy-[2-[(Z)-nonadec-9-enoyl]oxy-3-octoxypropoxy]phosphoryl]oxyethyl-trimethylazanium
2-[carboxy-[2-hydroxy-3-[(13Z,16Z,19Z,22Z,25Z)-octacosa-13,16,19,22,25-pentaenoyl]oxypropoxy]methoxy]ethyl-trimethylazanium
2-[[2-heptanoyloxy-3-[(Z)-icos-11-enoxy]propoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[3-nonoxy-2-[(Z)-octadec-9-enoyl]oxypropoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[2-propanoyloxy-3-[(Z)-tetracos-13-enoxy]propoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[3-dodecoxy-2-[(Z)-pentadec-9-enoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[2-tetradecanoyloxy-3-[(Z)-tridec-9-enoxy]propoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[3-[(Z)-nonadec-9-enoxy]-2-octanoyloxypropoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[2-[(Z)-tetradec-9-enoyl]oxy-3-tridecoxypropoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[3-[(Z)-docos-13-enoxy]-2-pentanoyloxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[2-[(Z)-hexadec-9-enoyl]oxy-3-undecoxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[3-decoxy-2-[(Z)-heptadec-9-enoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[3-[(Z)-henicos-11-enoxy]-2-hexanoyloxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[2-decanoyloxy-3-[(Z)-heptadec-9-enoxy]propoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[2-dodecanoyloxy-3-[(Z)-pentadec-9-enoxy]propoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
Menaquinone-7
A menaquinone whose side-chain contains seven isoprene units in an all-trans-configutation. D006401 - Hematologic Agents > D003029 - Coagulants > D006490 - Hemostatics
CerPE(33:0)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
